In the most recent data presented at the meeting, the CAR T-cell therapy demonstrated a 96 percent overall response rate.

Key Highlights Motixafortide effectively mobilized sufficient hematopoietic stem cells (HSCs) in patients with sickle cell disease enabling accelerated access to gene therapies 90% (9 of 10) of ...

The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an ...

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease ...

Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing ...

The CAR T Vision Steering Committee has set an ambitious goal: to double the proportion of eligible patients treated with CAR T by 2030. 2 Reimbursement challenges stand out as an area where ...

The "Middle East Cell and Gene Therapy CDMO Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The Middle East Cell and Gene Therapy CDMO market is poised for significant ...

CCRM and CCRM Nordic Announce Strategic Collaboration with IonQ at the Intersection of Advanced Therapies and Quantum Computing TORONTO, Canada and GOTHENBURG, Sweden, Dec. 1, 2025 /CNW/ - CCRM and ...

The unexpected bankruptcy of ASC Therapeutics has sent shockwaves through the Bay Area’s biotech community, cutting short ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...